MS4A1 and rheumatoid arthritis: Adequate specificity and reliability in anti-CD20 cell targeting using [89Zr]-rituximab PET have already been demonstrated in malignant lymphoma and rheumatoid arthritis by analyzing histology in mouse models and human application [13, 25–32].